{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:20:52Z","timestamp":1780327252449,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Science and technology project of Xuzhou City","award":["KC16SG255"],"award-info":[{"award-number":["KC16SG255"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejmech.2020.112522","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:15:43Z","timestamp":1593256543000},"page":"112522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H2S) donors as potent EGFR inhibitors against L858R resistance mutation"],"prefix":"10.1016","volume":"202","author":[{"given":"You-Guang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Yun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112522_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.32471\/exp-oncology.2312-8852.vol-41-no-1.12414","article-title":"Quinazoline compounds for antitumor treatment","volume":"41","author":"Solyanik","year":"2019","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.ejmech.2020.112522_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejmech.2019.03.030","article-title":"2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K","volume":"172","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib3","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bmcl.2015.02.025","article-title":"Synthesis, anticonvulsant activity and molecular modeling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone","volume":"25","author":"Al-Salem","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112522_bib4","first-page":"138","article-title":"Design and synthesis of novel pyrimidine\/hexahydroquinazoline-fused pyrazolo 3,4-b pyridine derivatives, their biological evaluation and docking studies(#)","volume":"4","author":"Pradeep","year":"2019","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2020.112522_bib5","series-title":"Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry","article-title":"Directed search of anti-inflammatory agents among (3H-Quinazoline-4-ylidene)hydrazides of N-protected amino acids and their heterocyclization products","author":"Yu V","year":"2019"},{"key":"10.1016\/j.ejmech.2020.112522_bib6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1021\/acs.jmedchem.7b00738","article-title":"Design and synthesis of orally bioavailable piperazine substituted 4(1H)-Quinolones with potent antimalarial activity: structure-activity and structure-property relationship studies","volume":"61","author":"Neelarapu","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1573409912666160126142236","article-title":"1-R-2-( 1,2,4 triazolo 1,5-c quinazoline-2-ylthio) etanon(ol) s: synthesis, bioluminescence inhibition, molecular docking studies, antibacterial and antifungal activities","volume":"12","author":"Antypenko","year":"2016","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.ejmech.2020.112522_bib8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/14756366.2013.845820","article-title":"Synthesis and characterization of quinazoline derivatives: search for hybrid molecule as diuretic and antihypertensive agents","volume":"29","author":"Rahman","year":"2014","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/14756366.2012.755622","article-title":"Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazoline-triazine derivatives","volume":"29","author":"Modh","year":"2014","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bmcl.2018.12.056","article-title":"Discovery of new quinazoline derivatives as irreversible dual EGFR\/HER2 inhibitors and their anticancer activities - Part 1","volume":"29","author":"Das","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112522_bib11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/bkcs.11491","article-title":"Allosteric inhibitor TREA-0236 containing non-hydrolysable quinazoline-4-one for EGFR T790M\/C797S mutants inhibition","volume":"39","author":"Lee","year":"2018","journal-title":"Bull. Kor. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.112522_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.bioorg.2018.07.015","article-title":"Dual EGFR\/HER2 inhibitors and apoptosis inducers: new benzo g quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers","volume":"80","author":"Ghorab","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/14756366.2018.1518957","article-title":"Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers","volume":"34","author":"Wang","year":"2019","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s10787-018-0471-3","article-title":"Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in\u00a0vitro cytotoxicity and in ovo antiangiogenic activity","volume":"26","author":"Pathak","year":"2018","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejmech.2020.112522_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.compbiolchem.2019.01.008","article-title":"Novel 2,4-disubstituted quinazolines as cytotoxic agents and JAK2 inhibitors: synthesis, in\u00a0vitro evaluation and molecular dynamics studies","volume":"79","author":"Buggana","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cbdd.13405","article-title":"Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer","volume":"93","author":"Chen","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112522_bib17","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1016\/j.bmcl.2018.08.039","article-title":"Discovery and lead identification of quinazoline-based BRD4 inhibitors","volume":"28","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112522_bib18","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.bmcl.2018.08.035","article-title":"Synthesis and biological evaluation of novel 5,6-dihydropyrimido 4,5-f quinazoline derivatives as potent CDK2 inhibitors","volume":"28","author":"Hu","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112522_bib19","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1039\/C8OB00286J","article-title":"Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1\/2 inhibitors: design, synthesis and their antitumor activity","volume":"16","author":"Zhou","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib20","first-page":"256","article-title":"4,6-Disubstituted quinazoline derivatives as inhibitors of the MEK5\/ERK5 pathway","author":"Patel","year":"2018","journal-title":"Abstr. Pap. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.112522_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2017.02.061","article-title":"Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors","volume":"130","author":"Zheng","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cbdd.12089","article-title":"Synthesis and quantum chemical studies of new 4-aminoquinazoline derivatives as aurora A\/B kinase inhibitors","volume":"81","author":"Zheng","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112522_bib23","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1016\/j.bmc.2010.04.046","article-title":"Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity","volume":"18","author":"Wu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib24","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1039\/c3mb70145j","article-title":"Synthesis and evaluation of phosphorodithioate-based hydrogen sulfide donors","volume":"9","author":"Park","year":"2013","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ejmech.2020.112522_bib25","first-page":"2969","article-title":"Anticancer effect of exogenous hydrogen sulfide in cisplatin-resistant A549\/DDP cells","volume":"39","author":"Ma","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2020.112522_bib26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3892\/ijo.2014.2305","article-title":"GYY4137, a hydrogen sulfide ( H2S) donor, shows potent anti- hepatocellular carcinoma activity through blocking the STAT3 pathway","volume":"44","author":"Lu","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2020.112522_bib27","doi-asserted-by":"crossref","first-page":"84338","DOI":"10.18632\/oncotarget.12609","article-title":"H2S-releasing nanoemulsions: a new formulation to inhibit tumor cells proliferation and improve tissue repair","volume":"7","author":"Ciocci","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2020.112522_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1389200219666180611083155","article-title":"The therapeutic role of xenobiotic nuclear receptors against metabolic syndrome","volume":"20","author":"Pu","year":"2019","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2020.112522_bib29","article-title":"The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in\u00a0vitro and in\u00a0vivo","volume":"6","author":"Lee","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112522_bib30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejmech.2018.04.009","article-title":"Antiproliferative hydrogen sulfide releasing evodiamine derivatives and their apoptosis inducing properties","volume":"151","author":"Hu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2018.10.002","article-title":"Hydrogen sulfide releasing enmein-type diterpenoid derivatives as apoptosis inducers through mitochondria-related pathways","volume":"82","author":"Xu","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1039\/c3md00185g","article-title":"Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential","volume":"4","author":"Kodela","year":"2013","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejmech.2020.112522_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1021\/ml300002m","article-title":"NOSH-aspirin: a novel nitric oxide-hydrogen sulfide-releasing hybrid: a new class of anti-inflammatory pharmaceuticals","volume":"3","author":"Kodela","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112522_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11060-018-2884-7","article-title":"GOLPH3 promotes glioma progression via facilitating JAK2-STAT3 pathway activation","volume":"139","author":"Wu","year":"2018","journal-title":"J.\u00a0Neuro Oncol."},{"key":"10.1016\/j.ejmech.2020.112522_bib35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/neuonc\/nox104","article-title":"Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor","volume":"19","author":"Zhou","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2020.112522_bib36","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112522_bib37","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1021\/acs.jmedchem.5b01611","article-title":"Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo 3,4-d pyrimidin-1-yl)p iperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia","volume":"58","author":"Li","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib38","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.0511292103","article-title":"An efficient rapid system for profiling the cellular activities of molecular libraries","volume":"103","author":"Melnick","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112522_bib39","article-title":"Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines","volume":"36","author":"La Monica","year":"2017","journal-title":"J.\u00a0Exp. Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112522_bib40","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bcpt.12940","article-title":"After treatment with methylene blue is effective against delayed encephalopathy after acute carbon monoxide poisoning","volume":"122","author":"Zhao","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2020.112522_bib41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1158\/1541-7786.MCR-18-1068","article-title":"Urea cycle sustains cellular energetics upon EGFR inhibition in EGFR-mutant NSCLC","volume":"17","author":"Pham-Danis","year":"2019","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112522_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejmech.2018.01.090","article-title":"6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells","volume":"147","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112522_bib43","article-title":"A\u00a0highly selective and sensitive near-infrared fluorescent probe for imaging of hydrogen sulphide in living cells and mice","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112522_bib44","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1021\/acs.jmedchem.5b01223","article-title":"Synthesis and pharmacological evaluation of novel adenine-hydrogen sulfide slow release hybrids designed as multitarget cardioprotective agents","volume":"59","author":"Lougiakis","year":"2016","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:10:18Z","timestamp":1759327818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420304943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":44,"alternative-id":["S0223523420304943"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112522","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H2S) donors as potent EGFR inhibitors against L858R resistance mutation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112522"}}